The Latest in Prostate Cancer Research and Treatment

2
prostate cancer, mark pomerantz

Mark Pomerantz, MD, (left) recently shared the latest prostate cancer news during a live video webchat with Dana-Farber.

Prostate cancer is the most common cancer affecting men in the United States, after skin cancer. Yet, “most men die with prostate cancer, not of prostate cancer,” says Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology, who recently shared the latest in prostate cancer research and treatment during a live video webchat.

During the chat, Pomerantz discussed one of the more controversial topics in prostate cancer: the PSA test, which measures the prostate-specific antigen and is a good marker for the amount of prostate tissue in the body. While informative, the test is not universally recommended in the U.S.

“If men are going to die with the disease rather than because of the disease, there are consequences to finding prostate cancer,” explains Pomerantz. “It leads to the psychological impact of having a cancer diagnosis and, more troubling, overtreatment of the disease.”

“On the other hand, we also want to save the lives of the 30,000 men each year who die of prostate cancer. It’s a very tricky balance,” Pomerantz adds.

While treatment has its side effects, for some men with a high Gleason score, high PSA number, or who have a large amount of tumor present, treatment can be curative. For those patients with lower-grade tumors, many oncologists take an “active surveillance” approach.

“Over time, we are more and more confident that we can safely manage patients without needing immediate cure,” says Pomerantz.

In addition to PSA testing, Pomerantz also discussed prostate cancer genetics and risk, the promise of gene therapy and immunotherapy, and the importance of clinical trials for prostate cancer. Learn more by watching a recording of the webchat below:

Comments Sort By Newest

2 thoughts on “The Latest in Prostate Cancer Research and Treatment

  1. Dear Robin —

    We are sorry to hear you are having trouble viewing the article. We are not aware of any issues at the moment, but our blog is usually best viewed in Chrome or Firefox. If you are still having trouble viewing the article, please email insight_blog@dfci.harvard.edu. Again, our apologies the article is not displaying correctly.

  2. Well I clicked on the “link” for what’s new in prostate cancer and as all I got was a picture of the doctors. No video no article. Very annoying

  3. Well I clicked on the “link” for what’s new in prostate cancer and as all I got was a picture of the doctors. No video no article. Very annoying

  4. Dear Robin —

    We are sorry to hear you are having trouble viewing the article. We are not aware of any issues at the moment, but our blog is usually best viewed in Chrome or Firefox. If you are still having trouble viewing the article, please email insight_blog@dfci.harvard.edu. Again, our apologies the article is not displaying correctly.

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Since 2014, more than 40 of Carol Snyder Halberstadt’s poems, including those focused on her ongoing care at Dana-F… https://t.co/NufLBIE2mk
Dana-Farber @danafarber
WATCH: Laurie H. Glimcher, MD, president and chief executive officer of Dana-Farber, at the World Economic Forum di… https://t.co/M9jAdexxAB

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.